Related coverage linked through entity extraction aliases.
May 18, 2026
The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
Mar 19, 2026
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Mar 13, 2026
Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.
Feb 28, 2026
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
Feb 20, 2026
Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.
Feb 24, 2026
New research demonstrates that dexamethasone effectively ameliorates cytokine-release syndrome in CAR T-cell therapy for multiple myeloma while maintaining or enhancing anti-tumor activity and increasing CAR T-cell levels.
Feb 24, 2026
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
